MedTrace Logo

A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

NCT05608876 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-08-07

No results posted yet for this study

Summary

A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.

Conditions

Interventions

DRUG

Tigilanol Tiglate

Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.

Sponsors & Collaborators

  • QBiotics Group Limited

    lead INDUSTRY

Principal Investigators

  • Richard Gallagher, MBBS · The Kinghorn Cancer Centre

  • David Owens, MBchB · Cardiff and Vale University Health Board - University Hospital of Wales (UHW)

  • Anthony Kong, MBBS · Guy's and St Thomas' NHS Foundation Trust

  • Joseph Sacco, MBchB · The Clatterbridge Cancer Centre NHS Foundation Trust

  • Benedict Panizza, MBBS MBA · Metro South Hospital and Health Service, via the Princess Alexandra Hospital

  • Kevin Harrington, BSc MBBS · Royal Marsden NHS Foundation Trust

  • George Mochloulis, MD CCST · East and North Hertfordshire NHS Trust (Incorporating Mount Vernon Cancer Centre) of Lister Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-03
Primary Completion
2025-07-31
Completion
2026-08-31

Countries

  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05608876 on ClinicalTrials.gov